FUTURE 2 Trial Shows Secukinumab to be Effective in Psoriatic Arthritis
Lancet today published the results of the phase 3, prospecitive, multinational, double-blind, randomized controlled trial of secukinumab (an anti-IL-17A monoclonal antibody) in active psoriatic arthritis.


